Neurocrine Biosciences, Inc.

Good day, everyone, and welcome to today's Neurocrine Biosciences Report's second quarter 2020 results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. You may register to ask a question at any time by pressing the star and 1 on your touch-tone phone. I will be standing by if you should need audio assistance, and it is now my pleasure to turn today's conference over to Todd Tushla, VP of Investor Relations. Please go ahead.

Thank you, Rylan. Good afternoon, everyone, and thank you for joining our Q2 2020 earnings call. Joining me on the call is Kevin Gorman, our Chief Executive Officer, Matt Abernethy, our Chief Financial Officer, Irie Roberts, our Chief Medical Officer, Eric Benevich, our Chief Commercial Officer, and Kyle Gano, our Chief Business Development and Strategy Officer. During today's call, we'll be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. With that, I now turn the call over to Kevin.

Thank you, Todd, and good afternoon, everyone. You know, I'm beginning to sound a little bit like a broken record, but here I like sounding like a broken record. This quarter, by any measure, has been remarkable. The impressive achievements across the entire organization is a great display of the resilience of our company. in this first full quarter that we've been living with COVID. This resilience is evident in our regulatory approvals, the advancement of our clinical programs, continued success of Ingresa, and the growth of our pipeline. Now, I'm certain the tenacity of our employees and that of all of our external partners will allow us to fulfill our mission throughout this pandemic. We are presented with the same challenges that COVID has presented to the entire biopharmaceutical industry. And yes, the fits and starts, the openings and closings in healthcare and the economy just adds to the fatigue everyone is experiencing. However, this is temporary. And we have shown that we are adaptable. But perhaps most importantly, the fundamentals of all aspects of our business are stronger than at any time in the history of neurocrine. Ingresa's importance to patients, their caregivers, and healthcare professionals now is objectively demonstrated by the continued high compliance rates of this past quarter. This unique environment where nearly 90% of patients interact with their physicians by telemedicine will moderate back to a more balanced mix of in-person and telemedicine. While we are certainly encouraged with Ingresa's impressive growth, Until more patients are seen in the doctor's office, we expect to see this continued impact on new patient starts, as we discussed in our last quarterly call.